Cargando…

Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies

Pretomanid is a nitroimidazole antimicrobial active against drug-resistant Mycobacterium tuberculosis and approved in combination with bedaquiline and linezolid (BPaL) to treat multidrug-resistant (MDR) pulmonary tuberculosis (TB). However, the penetration of these antibiotics into the central nervo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mota, Filipa, Ruiz-Bedoya, Camilo A., Tucker, Elizabeth W., Holt, Daniel P., De Jesus, Patricia, Lodge, Martin A., Erice, Clara, Chen, Xueyi, Bahr, Melissa, Flavahan, Kelly, Kim, John, Brosnan, Mary Katherine, Ordonez, Alvaro A., Peloquin, Charles A., Dannals, Robert F., Jain, Sanjay K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800570/ https://www.ncbi.nlm.nih.gov/pubmed/36581633 http://dx.doi.org/10.1038/s41467-022-35730-3

Ejemplares similares

1411. Noninvasive Assessment of Intralesional Antimicrobial Concentration-Time Profiles in Pulmonary and Central Nervous System Tuberculosis using Dynamic (18)F-Pretomanid Positron Emission Tomography
por: Mota, Filipa, et al.
Publicado: (2021)

191. High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis
por: Ruiz-Bedoya, Camilo A, et al.
Publicado: (2021)

High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis
por: Ruiz-Bedoya, Camilo A., et al.
Publicado: (2022)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

1954. Dynamic PET facilitated Modeling and Novel Antibiotic Regimens for Tuberculous Meningitis due to Multidrug-Resistant Strains
por: Chen, Xueyi, et al.
Publicado: (2023)

Molecular Imaging of Diabetic Foot Infections: New Tools for Old Questions
por: Ruiz-Bedoya, Camilo A., et al.
Publicado: (2019)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

(11)C-Para-aminobenzoic acid PET imaging of S. aureus and MRSA infection in preclinical models and humans
por: Ordonez, Alvaro A., et al.
Publicado: (2022)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Molecular Imaging: a Novel Tool To Visualize Pathogenesis of Infections In Situ
por: Gordon, Oren, et al.
Publicado: (2019)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
por: Baptista, Rafael, et al.
Publicado: (2018)

Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid
por: Thompson, Andrew M., et al.
Publicado: (2017)

(124)I-Iodo-DPA-713 Positron Emission Tomography in a Hamster Model of SARS-CoV-2 Infection
por: Ruiz-Bedoya, Camilo A., et al.
Publicado: (2021)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol
por: Lucas, Tobias, et al.
Publicado: (2023)

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
por: Lyons, Michael A.
Publicado: (2021)

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid
por: Abrahams, Katherine A., et al.
Publicado: (2023)

An improved radiosynthesis of [(18)F]FAraG, a PET radiotracer for imaging T‐cell activation
por: Holt, Daniel P., et al.
Publicado: (2022)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
por: Ambroso, Jeffrey L., et al.
Publicado: (2022)

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
por: Zou, Yuanxi, et al.
Publicado: (2022)

TB Meningitis and TB Peritonitis: Abdominal Pseudocyst and VP-Shunt Link
por: Ahmed, Manzoor, et al.
Publicado: (2019)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer
por: Nguyen, Hanh Thuy, et al.
Publicado: (2023)

Microglia activation in a pediatric rabbit model of tuberculous meningitis
por: Tucker, Elizabeth W., et al.
Publicado: (2016)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
por: Berry, Catherine, et al.
Publicado: (2022)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

An Infant with Xpert(®) Confirmed TB Meningitis in Central Viet Nam
por: Nguyen, Phuong T. K., et al.
Publicado: (2018)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h9bkjsgnen1gba8daj39o20o40